Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor

Blood

Volumn 113, Issue 8, 2009, Pages 1809-1817

  Reheman, Adili ^a,b   Yang, Hong ^a,b,c   Zhu, Guangheng ^b   Jin, Wuxun ^b   He, Feng ^b   Spring, Christopher M ^b   Bai, Xufang ^b,d   Gross, Peter L ^b,d   Freedman, John ^a,b   Ni, Heyu ^a,b,c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; COLLAGEN; FERROUS CHLORIDE; FIBRONECTIN; GLYCOPROTEIN IB ALPHA; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; CREMASTER MUSCLE; FEMALE; GEL FILTRATION; HEPARINIZATION; LAMINAR FLOW; MALE; MESENTERIC ARTERY; MICROSCOPY; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN DEPLETION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; THROMBOGENESIS;

EID: 61849083539     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-148361     Document Type: Article

References (51)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
2. Sachs UJ, Nieswandt B. In vivo thrombus formation in murine models. Circ Res. 2007;100:979-991.
3. Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost. 1997;78:611-616.
4. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392.
5. Yang H, RehemanA, Chen P, et al. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Hae-most. 2006;4:2230-2237.
6. Zhai Z, Wu J, Xu X, et al. Fibrinogen controls human platelet fibronectin internalization and cell-surface retention. J Thromb Haemost. 2007;5: 1740-1746.
7. Ni H, Papalia JM, Degen JL, Wagner DD. Control of thrombus embolization and fibronectin internal-ization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood. 2003;102: 3609-3614.
8. Ni H, Yuen PS, Papalia JM, et al. Plasma fi-bronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A. 2003;100:2415-2419.
9. Matuskova J, Chauhan AK, Cambien B, et al. Decreased plasma fibronectin leads to delayed thrombus growth in injured arterioles. Arterioscler Thromb Vasc Biol. 2006;26:1391-1396.
10. Olorundare OE, Peyruchaud O,Albrecht RM, Mosher DF. Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists. Blood. 2001;98:117-124.
11. Cho J, Degen JL, Coller BS, Mosher DF. Fibrin but not adsorbed fibrinogen supports fibronectin assembly by spread platelets. Effects of the interaction of alphaIIb beta3 with the C terminus of the fibrinogen gamma-chain. J Biol Chem. 2005;280: 35490-35498.
12. Cho J, Mosher DF. Impact of fibronectin assembly on platelet thrombus formation in response to type I collagen and von Willebrand factor. Blood. 2006;108:2229-2236.
13. Cho J, Mosher DF. Enhancement of thrombogen-esis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi. Blood. 2006; 107:3555-3563.
14. Ni H. Unveiling the new face of fibronectin in thrombosis and hemostasis. J Thromb Haemost. 2006;4:940-942.
15. Cho J, Mosher DF. Role of fibronectin assembly in platelet thrombus formation. J Thromb Hae-most. 2006;4:1461-1469.
16. Sakai T, Johnson KJ, Murozono M, et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med. 2001;7:324-330.
17. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin- deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999; 103:229-238.
18. Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A. 2000;97:2803-2808.
19. Ni H, Chen P, Spring CM, et al. A novel murine model of fetal and neonatal alloimmune thrombo-cytopenia: response to intravenous IgG therapy. Blood. 2006;107:2976-2983.
20. Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995;9:2020-2033.
21. Reheman A, Gross P, Yang H, et al. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Hae-most. 2005;3:875-883.
22. Bergmeier W, Schulte V, Brockhoff G, Bier U, Zirngibl H, Nieswandt B. Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry. 2002;48:80-86.
23. Zhu G, Webster M, RehemanA, et al. Novel mouse anti-mouse beta 3 integrin monoclonal antibodies: development and characterization of new reagents for research in thrombosis and thrombocytopenia [abstract]. Blood, 2007;118: 627a.
24. Jones KL, Hughan SC, Dopheide SM, Farndale RW, Jackson SP, Jackson DE. Platelet endothe-lial cell adhesion molecule-1 is a negative regulator of platelet-collagen interactions. Blood. 2001; 98:1456-1463.
25. Ni H, Ramakrishnan V, Ruggeri ZM, Papalia JM, Phillips DR, Wagner DD. Increased thrombogen-esis and embolus formation in mice lacking glyco-protein V. Blood. 2001;98:368-373.
26. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med. 2002;8:1175-1181.
27. Santoro SA. Inhibition of platelet aggregation by fibronectin. Biochem Biophys Res Commun. 1983;116:135-140.
28. Moon DG, Kaplan JE, Mazurkewicz JE. The inhibitory effect of plasma fibronectin on collagen-induced platelet aggregation. Blood. 1986;67: 450-457.
29. Hynes R. Fibronectin. New York, NY: Springer Verlag; 1990:546.
30. Moon DG, Matayoshi BM, Weston LK, Minnear FL, Kaplan JE. Fibronectin inhibition of platelet thrombus formation in an in vivo porcine model of vascular injury. Thromb Res. 1994;76:343-351.
31. Arneson MA, Hammerschmidt DE, Furcht LT, King RA.Anew form of Ehlers-Danlos syndrome. Fibronectin corrects defective platelet function. JAMA. 1980;244:144-147.
32. Dixit VM, Haverstick DM, O'Rourke K, et al. Inhibition of platelet aggregation by a monoclonal antibody against human fibronectin. Proc Natl Acad Sci U S A. 1985;82:3844-3848.
33. Cho J, Mosher DF. Characterization of fibronectin assembly by platelets adherent to adsorbed laminin-111. J Thromb Haemost. 2006;4:943-951.
34. Isenberg JS, Romeo MJ, Yu C, et al. Throm-bospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/ cGMP signaling. Blood. 2008;111:613-623.
35. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell. 2003;112:87-97.
36. Chauhan AK, Kisucka J, Cozzi MR, et al. Pro-thrombotic effects of fibronectin isoforms containing the EDA domain. Arterioscler Thromb Vasc Biol. 2008;28:296-301.
37. Ni H, Freedman J. Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus Apher Sci. 2003;28:257-264.
38. Jackson SP. The growing complexity of platelet aggregation. Blood. 2007;109:5087-5095.
39. BonnefoyA, Hantgan R, Legrand C, Frojmovic MM. A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrino-gen, and GPIIbIIIa receptor. J Biol Chem. 2001; 276:5605-5612.
40. Wu YP, Bloemendal HJ, Voest EE, et al. Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homo-typic interactions with platelet-associated vitronectin. Blood. 2004;104:1034-1041.
41. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.
42. Plow EF, Cierniewski CS, Xiao Z, Haas TA, Byzova TV. AlphaIIbbeta3 and its antagonism at the new millennium. Thromb Haemost. 2001;86: 34-40.
43. Chen VM, Hogg PJ. Allosteric disulfide bonds in thrombosis and thrombolysis. J Thromb Haemost. 2006;4:2533-2541.
44. Cho J, Furie BC, Coughlin SR, Furie B. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest. 2008;118:1123-1131.
45. Langenbach KJ, Sottile J. Identification of protein-disulfide isomerase activity in fibronectin. J Biol Chem. 1999;274:7032-7038.
46. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci U S A. 1992;89:3531-3535.
47. Mosher DF. Plasma fibronectin concentration: a risk factor for arterial thrombosis? Arterioscler Thromb Vasc Biol. 2006;26:1193-1195.
48. Orem C, Celik S, OremA, Calapoglu M, Erdol C. Increased plasma fibronectin levels in patients with acute myocardial infarction complicated with left ventricular thrombus. Thromb Res. 2002;105: 37-41.
49. Orem C, Durmus I, Kilinc K, et al. Plasma fi-bronectin level and its association with coronary artery disease and carotid intima-media thickness. Coron Artery Dis. 2003;14:219-224.
50. Song KS, Kim HK, Shim W, Jee SH. Plasma fi-bronectin levels in ischemic heart disease. Atherosclerosis. 2001;154:449-453.
51. Pecheniuk NM, Elias DJ, Deguchi H,Averell PM, Griffin JH. Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb Haemost. 2008;100:224-228.